[HTML][HTML] Apoptotic cell death in disease—Current understanding of the NCCD 2023

I Vitale, F Pietrocola, E Guilbaud… - Cell Death & …, 2023 - nature.com
Apoptosis is a form of regulated cell death (RCD) that involves proteases of the caspase
family. Pharmacological and genetic strategies that experimentally inhibit or delay apoptosis …

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

M Hallek, O Al‐Sawaf - American journal of hematology, 2021 - Wiley Online Library
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

[HTML][HTML] Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia

AR Mato, JA Woyach, JR Brown, P Ghia… - … England Journal of …, 2023 - Mass Medical Soc
Background Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …

[HTML][HTML] First-line venetoclax combinations in chronic lymphocytic leukemia

B Eichhorst, CU Niemann, AP Kater… - … England Journal of …, 2023 - Mass Medical Soc
Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …

Targeting apoptosis in cancer therapy

BA Carneiro, WS El-Deiry - Nature reviews Clinical oncology, 2020 - nature.com
For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

AH Wei, P Montesinos, V Ivanov… - Blood, The Journal …, 2020 - ashpublications.org
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …

ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic …

P Ghia, A Pluta, M Wach, D Lysak, T Kozak… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …

Programming inflammatory cell death for therapy

S Christgen, RE Tweedell, TD Kanneganti - Pharmacology & therapeutics, 2022 - Elsevier
Programmed cell death (PCD) is an essential part of organismal development and plays
fundamental roles in host defense against pathogens and the maintenance of homeostasis …

Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study

AH Wei, SA Strickland Jr, JZ Hou, W Fiedler… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …

[HTML][HTML] The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy

G Pavlasova, M Mraz - Haematologica, 2020 - ncbi.nlm.nih.gov
The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …